Chmp

US drug maker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Sanofi-aventis has announced that following the review of the available evidence on Lantus, (insulin glargine [rDNA] injection), the European Medicines Agence's Committee for Medicinal products for human use (CHMP) confirmed the product's safety and concluded that changes to the prescribing advice are not necessary.The CHMP issued a press-release s...

US drug maker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Sanofi-aventis has announced that following the review of the available evidence on Lantus, (insulin glargine [rDNA] injection), the European Medicines Agence's Committee for Medicinal products for human use (CHMP) confirmed the product's safety and concluded that changes to the prescribing advice are not necessary.The CHMP issued a press-release s...